T3-T4 laryngeal cancer in The Netherlands Cancer Institute; 10-year results of the consistent application of an organ-preserving/-sacrificing protocol
ABSTRACT Background Both organ‐preserving concurrent (chemo)radiotherapy ((C)RT) and organ‐sacrificing surgery (total laryngectomy) are used for treatment of advanced laryngeal cancer. The purpose of this study was to present the assessment of our treatment protocol for T3 (C)RT and T4 disease (tota...
Saved in:
Published in | Head & neck Vol. 37; no. 10; pp. 1495 - 1503 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.10.2015
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | ABSTRACT
Background
Both organ‐preserving concurrent (chemo)radiotherapy ((C)RT) and organ‐sacrificing surgery (total laryngectomy) are used for treatment of advanced laryngeal cancer. The purpose of this study was to present the assessment of our treatment protocol for T3 (C)RT and T4 disease (total laryngectomy + postoperative RT).
Methods
We conducted a retrospective cohort study in 182 consecutive patients (1999–2008). The primary outcome was overall survival (OS) in relation to stage and treatment.
Results
One hundred two patients received RT (82.4% T3), 20 patients CRT (60.0% T3), and 60 patients total laryngectomy + RT (91.7% T4). Five‐year OS: T3 52%, T4 48%, for RT 50%, for CRT 43%, and for total laryngectomy + RT 52%. Five‐year laryngectomy‐free interval was 72% after RT, and 83% after CRT.
Conclusion
There were no differences in survival according to T classification or treatment modality. Because the majority of T3 laryngeal cancers were treated with (C)RT and the majority of T4 with total laryngectomy + RT, this gives food for thought on whether the present protocol for T3 laryngeal cancer is optimal. © 2014 Wiley Periodicals, Inc. Head Neck 37: 1495–1503, 2015 |
---|---|
Bibliography: | ark:/67375/WNG-29Z0T2FF-Z The Department of Head and Neck Oncology and Surgery of the Netherlands Cancer Institute receives an unrestricted research grant from Atos Medical, Sweden. istex:08E1DE4FA6E81B4707DC5BA1DC7DADE453C33F59 ArticleID:HED23789 This work in the form of an e‐poster was presented at the annual meeting of the Dutch Head and Neck Society, March 14–15, 2013, and at the 20th IFOS World Congress in Seoul, Korea, June 1–5, 2013. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1043-3074 1097-0347 |
DOI: | 10.1002/hed.23789 |